CBT

Cabot Corporation 10-Q Summary: Quarter Ended March 31, 2005

Business Context and Reporting Period

This filing is a Quarterly Report (Form 10-Q) for Cabot Corporation for the three and six months ended March 31, 2005. Cabot is a specialty chemicals company organized into three reportable segments: Chemicals (carbon black, fumed metal oxides, inkjet colorants, aerogels), Supermetals (tantalum and related products), and Specialty Fluids (cesium formate). The company operates globally with significant manufacturing and sales in the U.S. and Europe.

Key Financial Metrics

Note: Q2 2005 results include a non-cash goodwill impairment charge of $90 million.

Material Changes vs. Prior Period

• Goodwill Impairment: The primary driver of the net loss was a $90 million non-cash impairment charge related to the Supermetals business. Management determined the fair value of the reporting unit was below its carrying amount due to trends toward smaller tantalum capacitors, high supply chain inventory, and expected decreases in volume and pricing.
• Revenue Growth: Net sales increased 5% in Q2 and 11% for the six-month period, driven by higher volumes and pricing, particularly in the Chemicals segment.
• Segment Performance:
  • Chemicals: Sales increased 7% (Q2) and 11% (6 months). Profitability improved due to higher prices and volumes offsetting raw material costs.
  • Supermetals: Sales were relatively flat in Q2 but down 5% for the six months. Operating profit before the impairment charge remained relatively stable.
  • Specialty Fluids: Sales were flat in Q2 but increased for the six months due to a higher number of jobs completed.
• Restructuring: The company recorded $4 million in restructuring charges for Q2 and $8 million for the six months, primarily related to the closure of the Altona, Australia carbon black plant and European restructuring activities.

Guidance, Outlook, and Risks

• Outlook: Management expects the effective tax rate for fiscal 2005 to be between 24% and 28%, excluding goodwill impairment and tax audit settlements. Capital expenditures for fiscal 2005 are expected to exceed $200 million.
• Liquidity: The company maintains $156 million in cash and cash equivalents. Management expects cash on hand, operating cash flow, and existing financing arrangements (including an unused line of credit) to be sufficient for the next 12 months. A $86 million yen term loan matures in October 2005 and is expected to be refinanced.
• Legal and Contingencies:
  • Respirator Litigation: Approximately 92,000 claimants are pending. The company has an $18 million reserve (net present value) for these claims.
  • Antitrust: The company is involved in European and U.S. antitrust investigations regarding carbon black pricing. No charges have been filed against Cabot or its employees.
  • Beryllium Claims: Various personal injury and medical monitoring claims are pending related to discontinued beryllium operations.
• Accounting Changes: The company revised its revenue recognition policy for a specific Supermetals product to defer revenue until customer acceptance. The impact was not material. The company is also evaluating the impact of FAS 123R (Share-Based Payment) and FAS 151 (Inventory Costs), effective October 1, 2005.

Investor Verification Checklist

• Verify the assumptions used in the $90 million Supermetals goodwill impairment analysis, specifically regarding future tantalum powder volumes and pricing.
• Monitor the progress of the $86 million yen term loan refinancing due in October 2005.
• Review updates on the respirator litigation reserve ($18 million) and the potential impact of the excluded Mississippi settlement data.
• Track the execution of the Altona, Australia plant closure and associated restructuring costs ($18 million total estimated charge).
• Assess the impact of the American Jobs Creation Act of 2004 on the company's tax position, particularly regarding the repatriation of foreign earnings.